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Purpose: Patients with non-small cell lung carcinoma with epider-
mal growth factor receptor (EGFR) mutations may have a more
favorable prognosis and greater response to chemotherapy. The
effect of EGFR mutation and gene copy on patients with early-stage
non-small cell lung carcinoma receiving adjuvant chemotherapy has
not been reported.
Patients and Methods: Tumor samples from NCIC Clinical Trials
Group JBR.10, an adjuvant trial of vinorelbine/cisplatin adjuvant
chemotherapy [ACT] versus observation (OBS), were analyzed for
EGFR mutation by multiple sensitive methods and copy number by
fluorescent in situ hybridization. Their prognostic and predictive
roles were explored in correlation with survival.
Results: Mutation results were available in 221 OBS and 215 ACT
and fluorescent in situ hybridization results in 159 OBS and 163
ACT patients. Mutations were identified in 43 (27 OBS and 16
ACT) patients (36 sensitizing exon 19 deletions or L858R muta-
tions). Compared with wild-type, sensitizing mutations were not
significantly prognostic in OBS patients (hazard ratio [HR]: 0.79,
95% confidence interval [CI]: 0.38–1.63, p  0.53). Although the
presence of sensitizing mutations resulted in relatively greater ben-
efit in ACT patients (HR: 0.44, 95% CI: 0.11–1.70, p  0.22)
compared with wild-type patients (HR: 0.78, 95% CI: 0.58–1.06,
p  0.12), this quantitative difference was not significant (interac-
tion p  0.50). Similarly, high EGFR copy was neither significantly
prognostic nor predictive, although quantitatively it was associated
with greater benefit from ACT.
Conclusions: Trends toward longer survival and a greater benefit
from chemotherapy were observed in patients with exon 19/21
mutations and high EGFR copy, although the differences were not
statistically significant. The interpretation of the results was limited
by the low EGFR mutation rate in this study of mainly white
patients.
Key Words: Biomarker, Prognostic marker, Predictive marker,
Sequencing, FISH, Clinical trial, Correlative science.
(J Thorac Oncol. 2011;6: 139–147)
Patients with early-stage non-small cell lung carcinoma(NSCLC) are treated surgically with curative intent; how-
ever, 30 to 65% develop recurrence and die of their disease.1
Recent trials using cisplatin-based doublet chemotherapy and
meta-analyses have demonstrated significant survival benefits
with postoperative chemotherapy.2–5 JBR.10, a North Amer-
ican intergroup study led by the NCIC Clinical Trials Group,
randomized patients with completely resected stage IB to
stage II NSCLC to receive adjuvant chemotherapy with
cisplatin/vinorelbine or observation (OBS) alone. Chemo-
therapy-treated patients derived significant survival benefit
(hazard ratio [HR]: 0.70, p  0.03).5,6 It is recognized that
certain clinical and pathologic factors such as stage, age, sex,
tumor histology, and differentiation grade are prognostic of
outcome in NSCLC.7 At the molecular level, although a large
number of markers have been investigated for their prognos-
tic value,8 few have been reported to predict a differential
effect of adjuvant chemotherapy on survival.9 Currently,
apart from stage, neither prognostic nor predictive markers
are used routinely to select patients with NSCLC for adjuvant
chemotherapy.
Greater than 60% of NSCLC tumors express epidermal
growth factor receptor (EGFR) protein.10 The discovery that
EGFR tyrosine kinase (TK) domain mutations are strongly
associated with greater sensitivity of NSCLC to EGFR TK
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inhibitors (TKIs) and that mutations are more common
among patient subgroups who demonstrate response to these
drugs suggests that this or other molecular markers may be
used to determine patient subgroups most likely to benefit
from EGFR TKI therapy.11,12 Recent studies have shown that
patients whose tumors contain EGFR-activating mutations on
exons 19 and 21 also demonstrate higher response rates to
chemotherapy.13,14 EGFR gene copy gain also has been
shown to be a predictive marker for response and survival
benefit with EGFR TKI therapy15,16 but has not been shown
to be associated with a differential response to chemothera-
py.14–18 We report in this study our analyses of EGFR TK
domain (TKD) mutation and gene copy number status in
patients from the JBR.10 trial and correlate these markers
with prognosis in the untreated control arm and survival
benefit from chemotherapy.
METHODS
Patients and Tissue
This molecular correlative study was approved by the
Research Ethics Board of the University Health Network.
JBR.10 compared the effect of adjuvant vinorelbine/cisplatin to
OBS alone in 482 patients with completely resected T2N0,
T1-2N1 NSCLC.5 Patients provided written consent for the
study and for RAS mutational analyses (RAS mutation status was
a stratification parameter) and 445 patients consented to tumor
banking for future studies (Supplementary Figure 1S, http://
links.lww.com/JTO/A40). These included snap-frozen tissue
with or without formalin-fixed, paraffin-embedded (FFPE)
blocks from 171 patients, FFPE blocks only from 161 patients,
and 10 unstained slides only from 119 patients. Tissue microar-
rays (TMAs) were constructed from 332 cases with FFPE
blocks.
Analysis for EGFR TKD Mutations
The methods for isolation of genomic DNA and anal-
ysis of mutations on EGFR exons 19 and 21 have been
reported previously.15 For samples that were estimated by
histology to have less than 50% tumor cellularity, we per-
formed macrodissection of unstained sections to enrich for
tumor DNA. DNA samples were analyzed first by direct
sequencing, and positive results were confirmed by repeat
sequencing of an independent polymerase chain reaction
product. Negative cases were screened secondarily using the
higher sensitivity fragment length analysis method to detect
exon 19 deletion and L858R mutations.19 Newly identified
deletion/mutations were confirmed by the Scorpion Ampli-
fied Refractory Mutation System (DxS, ARMS, Manchester,
UK). Samples were classified as failed or indeterminate if
repeated analyses failed or were unable to confirm mutations
on exons 19 or 21.15
EGFR Gene Copy Analysis
EGFR gene copy number was evaluated by fluorescent
in situ hybridization (FISH), as described previously using
the Vysis LSI EGFR probe labeled with Spectrum Orange,
and the CEP7 chromosome 7 centromere (7p11.1 through
q11.1) probe labeled with Spectrum Green.16 This was con-
ducted using TMA constructed from 332 cases with tumor
FFPE blocks. In 18 cases for which TMA cores showed
heterogeneity with the presence of both high and low copy
number cores, we repeated the analysis using full sections. To
validate TMA results further, full section analyses were also
conducted on 23 randomly chosen cases with EGFR ampli-
fication and 20 cases with low copy number (trisomy and low
polysomy). Six FISH categories were used to define EGFR
FISH status.15 Tumors with high EGFR gene copy (“High
EGFR copy”) included high polysomy or amplification, and
all other categories were classified as “Low EGFR copy.”
Statistical Analyses
Based on a prespecified statistical analysis plan, explor-
atory analyses were performed to characterize relationships
between marker levels and baseline clinical characteristics
and survival.4 Chi square or Fisher’s exact test was used to
test association between marker levels and baseline factors;
Kaplan-Meier product-limit method and the log-rank test
were used to estimate and test overall survival distributions
and their difference between marker levels and treatment
arms, and multivariate Cox regression models were used to
verify the prognostic and predictive effects of markers on
survival while adjusting for baseline factors and potential
prognostic factors including sex, age, performance status,
stage, histology, smoking status, baseline anemia, type of
resection, serum lactate dehydrogenase, p53 mutation status,
and p53 immunohistochemistry. All reported p values are two
sided, and a level of 5% (p  0.05) was considered statisti-
cally significant. To be consistent with our other mutational
analysis reports, survival analyses are based on the original
survival analysis of the trial.
RESULTS
EGFR TKD Mutation
Altogether, 445 patients who consented to future mo-
lecular studies had DNA available for mutation analysis.
Among these, failed or indeterminate results were obtained in
only nine patients. Baseline stratification and potential prog-
nostic factors for 436 patients with and 46 patients without
EGFR mutation results are shown in Supplemental Table 1S
(http://links.lww.com/JTO/A41). More patients with muta-
tion data were ever smokers (94.5% versus 84.8%, p 
0.027); there were no other significant differences between
the populations. In patients with mutation results, the survival
benefit from chemotherapy was similar to that of the overall
study (HR: 0.77, 95% confidence interval [CI]: 0.57–1.03,
p  0.08).
Forty-five mutations were found in samples from 43
patients (9.9%), with two tumors having two separate muta-
tions (Del E746_750, I744V; G735S, L858R). Female pa-
tients were more likely to have mutations (13.4% versus
8.0%, p 0.07), as were lifetime never smokers (40% versus
8.3%, p  0.001) and patients with adenocarcinoma (13.9%
versus 4.9% for squamous and 7.0% for other histologies,
p  0.01) (Table 1). Each case of squamous cell carcinoma
with mutation was reviewed histologically, and the diagnosis
was confirmed for all. Among nonwhite ethnicity patients,
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there were 10 native Hawaiian/Pacific islanders, who dem-
onstrated a mutation rate (40%) comparable with rates re-
ported among East Asian patients (Table 2).20
When considering all EGFR mutations, 27 patients in
the OBS arm with tumors that had mutations (Figure 1A)
showed numerically (but not significantly) longer overall
(adjusted HR: 0.68, 95% CI: 0.34–1.36, p  0.28) and
relapse-free (adjusted HR: 0.83, 95% CI: 0.44–1.56, p 
0.56) survivals compared with wild-type patients (Table 3).
Among these 27 patients, 22 had exon 19 deletions or L858R
mutations that are known to confer sensitivity (sensitizing
mutations) to both EGFR TKI therapy and chemotherapy
(Supplemental Table 2S, http://links.lww.com/JTO/A41).
The adjusted survivals of these 22 patients with sensitizing
mutations also were longer but not significantly different
compared with wild-type patients (overall survival HR: 0.73,
95% CI: 0.35–1.52, p  0.41) (Table 3, Figure 1B).
Both patients with wild-type and mutated EGFR (Table
4, Figure 1C) had survival benefit from adjuvant chemother-
apy (wild type, HR: 0.76, 95% CI: 0.56–1.04, p  0.08 and
mutants, HR: 0.65, 95% CI: 0.20–2.14, p  0.48). The
patients with sensitizing mutations seemed to derive even
greater (although statistically nonsignificant) survival benefit
from adjuvant chemotherapy (HR: 0.44, 95% CI: 0.11–1.70,
p  0.22, interaction p  0.50) (Table 4, Figure 1D).
Nevertheless, multivariate Cox regression analysis failed to
detect significant interaction between chemotherapy with
all-type mutations or sensitizing mutations, for either overall
survival (p 0.99 and p 0.53) or relapse-free survival (p
0.43 and p  1.00).
EGFR Copy Number
FISH results were obtained in only 322 patients for
whom we had paraffin blocks to construct TMAs. The base-
line stratification and potential prognostic factors are shown
for patients with and without EGFR FISH results in Supple-
mental Table 3S (http://links.lww.com/JTO/A41). More pa-
tients with FISH data were stage IB (51.6% versus 33.1%,
p  0.001), older than 65 years (35.4% versus 25.6%, p 
0.03), and ever smokers (95.3% versus 90.0%, p  0.06);
there were no other significant differences between the pop-
ulations. There was a nonsignificant difference (interaction
p  0.14) in survival benefit from chemotherapy between
patients with FISH results (HR: 0.83, 95% CI: 0.59–1.16,
p 0.28) and patients without FISH data (HR: 0.51, 95% CI:
0.530–0.86, p  0.01). Female patients were more likely to
have high EGFR copy (74.8% versus 55.5%, p  0.001), but
there were no significant differences in histologic subtype,
smoking history, or ethnicity between the groups (Table 1).
To verify the validity of FISH results obtained from TMA
analysis, we conducted independent FISH analyses on whole
tumor sections of 23 cases with EGFR amplification in TMA
cores and 20 cases with EGFR low copy. Discrepancy was found
in only 1 of 23 (4.3%) amplified and in 1 of 20 (5%) low copy cases
(Supplemental Table 4S, http://links.lww.com/JTO/A41). In 18
cases with TMA showing heterogeneous cores, some of
which had high polysomy and/or amplification, full section
analysis resulted in only two cases that were subsequently
scored as low copy number tumors (Supplemental Table 4S,
http://links.lww.com/JTO/A41).
Among 159 OBS patients (Figures 2A, B; Table 3),
there was no significant difference in overall survival be-
tween EGFR high (amplification  high polysomy) and
low-copy patients (HR: 0.74, 95% CI: 0.46–1.19, p  0.22).
TABLE 1. Baseline Clinical and Pathological Demographics According to EGFR Gene Status
Variables Demographics
EGFR Wild
Type (n  393)
EGFR Mutant
(n  43) pa
EGFR Low Gene
Copy (n  122)
EGFR High Gene
Copy (n  200) pa
Sex Male 264 (92.0%) 23 (8.0%) 0.072 94 (44.5%) 117 (55.5%) 0.001
Female 129 (86.6) 20 (13.4%) 28 (25.2%) 83 (74.8%)
Histology Squamous 154 (95.1%) 8 (4.9%) 43 (36.4%) 75 (63.6%)
Adenocarcinoma 199 (86.1%) 32 (13.9%) 0.010 70 (40.5%) 103 (59.5%) 0.444
Other 40 (93.0%) 3 (7.0%) 9 (29.0%) 22 (71.0%)
Smoking Never smoked 12 (60.0%) 8 (40.0%) 2 (15.4%) 11 (84.6%)
Ever smoked 378 (91.7%) 34 (8.3%) 0.001 119 (38.8%) 188 (61.2%) 0.142
Missing 3 (75.0%) 1 (25.0%) 1 (50.0%) 1 (50.0%)
Ethnicity White 175 (89.7%) 20 (10.3%) 43 (35.2%) 79 (64.8%)
Othersb 21 (77.8%) 6 (22.2%) 0.102 1 (8.3%) 11 (91.7%) 0.103
Unknown 197 (92.1%) 17 (7.9%) 78 (41.5%) 110 (58.5%)
a p value of 2 test without missing values.
b All 6 patients with EGFR mutations were pacific islanders.
EGFR, epidermal growth factor receptor.
TABLE 2. EGFR Mutation Rates among 27 Patients of
Different Nonwhite Ethnicity
Mutant (%)
Wild
Type (%) Total
Hispanic/Latino 0 1 (100) 1
African American 2 (17) 10 (83) 12
Native Hawaiian/Pacific
Islander
4 (40) 6 (60) 10
American/Alaska Native 0 3 (100) 3
Other 0 1 (100) 1
EGFR, epidermal growth factor receptor.
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TABLE 3. Impact of EGFR Status on the Survival of Patients in the Observation Arm by
Multivariate Analysisa
Relapse-Free Survival Overall Survival
Hazard
Ratio
95% Confidence
Interval p
Hazard
Ratio
95% Confidence
Interval p
EGFR tyrosine kinase
domain mutation status
Wild type (n  194) 1.0 — — 1.0 — —
All mutations (n  27) 0.83 0.44–1.56 0.56 0.68 0.34–1.36 0.28
Exon-19 deletions  L858R
mutation (n  22)
0.92 0.48–1.76 0.79 0.73 0.35–1.52 0.41
EGFR gene copy number
Low copy (n  60) 1.0 — — 1.0 — —
High copy (n  99)b 0.94 0.60–1.48 0.79 0.74 0.46–1.19 0.22
Amplification (n  29)c 1.24 0.69–1.23 0.48 1.10 0.58–2.05 0.78
a Multivariate adjustment includes other potential prognostic factors including sex, age, performance status, stage, histology,
smoking status, baseline anemia, resection, serum LDH, p53 mutation status, and immunohistochemistry.
b High copy includes high polysomy and amplification; survival compared with low polysomy or less copy number status.
c Survival compared with all patients without amplification.
EGFR, epidermal growth factor receptor.
FIGURE 1. A, comparison of the survival of patients with wild-type EGFR or any EGFR mutation in the observation arm. B,
comparison of the survival of patients with wild-type EGFR or exon 19 and 21 EGFR mutations in the observation arm. C, com-
parison of the survival of patients with wild-type EGFR in the chemotherapy and observation arms. D, comparison of the sur-
vival of patients with exon 19 and 21 EGFR mutations in the chemotherapy and observation arms. EGFR, epidermal growth
factor receptor.
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EGFR amplification was also not prognostic (HR: 1.10, 95%
CI: 0.58–2.05, p  0.78).
In 122 EGFR low-copy patients, 60 were on OBS,
whereas 62 received chemotherapy; there was no apparent
overall survival benefit from adjuvant chemotherapy (HR:
0.96, 95% CI: 0.58–1.60, p  0.88) (Figure 2C, Table 4). In
contrast, EGFR high copy patients treated by adjuvant che-
motherapy (n  101) had longer survival compared with
OBS patients (n  99), although the difference was not
significant (HR: 0.73, 95% CI: 0.47–1.44, p  0.17; interac-
tion p  0.47) (Figure 2D, Table 4). Similar survival benefit
from chemotherapy was noted in patients with EGFR high
copy number but wild-type gene (Figure 2E, HR: 0.77, 95%
CI: 0.48–1.23, p  0.27) and in patients with EGFR ampli-
fication only (Figure 2F, HR: 0.67, 95% CI: 0.32–1.41, p 
0.29). The trend toward greater survival benefit from che-
motherapy in EGFR high copy patients was stronger for
relapse-free survival (Table 4, HR: 0.58, 95% CI: 0.37–
0.90, p  0.015), especially among patients with EGFR
amplification (HR: 0.45, 95% CI: 0.21–0.97, p  0.036),
but the interaction p value remained insignificant (p  0.51
and 0.32, respectively). In multivariate analysis, EGFR
copy number was neither a prognostic nor a predictive
factor.
DISCUSSION
In this study, we evaluated the prognostic significance
of EGFR TKD mutations and EGFR gene copy gains, as well
as their potential impact on outcomes after adjuvant vinorel-
bine/cisplatin in patients from JBR.10, a pivotal randomized
study that included prospective collection of tumor samples.
Our results support previous reports that untreated patients
with NSCLC with EGFR mutations have longer survival
(HR: 0.68, p  0.28) compared with patients with wild-type
tumors in adjusted analysis, confirming the prognostic effect
identified in patients with advanced disease. In contrast, this
effect was not seen for EGFR amplification (overall survival
HR: 1.07, p  0.80). Exon 19 deletions or exon 21 L858R
sensitizing mutations were associated with a trend toward
greater benefit from adjuvant chemotherapy compared with
EGFR wild-type patients, although the difference was not
significant (HR: 0.44 versus 0.76, interaction p  0.5).
Similar, but also nonsignificant effects (interaction p  0.47)
were demonstrated for high EGFR gene copy (overall sur-
vival HR: 0.73, p  0.17), when compared with low copy
(HR: 0.96, p  0.88). Although numbers were small, we also
provide the first evidence that Hawaiian patients with NSCLC
have an EGFR mutation rate comparable with that found in
East-Asian patients.
It is only 6 years since the first reports showing that
patients whose tumors contained activating mutations in the
TK domain of the EGF receptor had higher response rates to
EGFR TKIs.11,12 This was confirmed subsequently in larger
retrospective studies from randomized trials of both erlotinib
and gefitinib.13–15 Nevertheless, the randomized trials of sin-
gle-agent EGFR TKI compared with a placebo control arm
did not confirm a significant differentially greater overall
survival benefit from erlotinib, despite the lower HR for
patients with mutations.15 The lack of significant interaction
may have been due to the small number of patients with
mutations in each trial. It has also been postulated that the
lack of differential benefit was due to the untreated patients
with mutations having an inherently better prognosis than
those with wild-type tumors.20 The evidence for this was
observed first in the Tarceva response in conjunction with
paclitaxel (TRIBUTE) trial of chemotherapy with or without
erlotinib.21 Regardless of therapy received, patients with
EGFR mutations in TRIBUTE had significantly better sur-
vival compared with those with wild-type tumors. Several
subsequent studies involving patients with resected NSCLC
or lung adenocarcinoma, also have reported better prognosis
for patients with EGFR mutations, although not all studies
have shown significant differences in prognosis in multivar-
iate analysis when other important variables have been in-
TABLE 4. Survival Benefit from Adjuvant Chemotherapy According to EGFR Gene Status
Relapse-Free Survival Overall Survival
Hazard
Ratioa
95%
Confidence
Interval p
p
Interaction
Hazard
Ratioa
95%
Confidence
Interval p
p
Interaction
EGFR tyrosine kinase domain
mutation status
Wild type (n  393) 0.65 0.48–0.89 0.006 0.76 0.56–1.04 0.08
All mutations (n  43) 0.78 0.30–2.00 0.60 0.62 0.65 0.20–2.14 0.48 0.86
Exon-19 deletions  L858R
mutation (n  36)b
0.58 0.21–1.60 0.29 0.98 0.44 0.11–1.70 0.22 0.50
EGFR gene copy number
Low copy (n  122) 0.73 0.44–1.22 0.23 0.96 0.58–1.60 0.88
High copy (n  200)c 0.58 0.37–0.90 0.015 0.51 0.73 0.47–1.14 0.17 0.47
Amplification (n  67)a 0.45 0.21–0.97 0.036 0.26 0.67 0.32–1.41 0.29 0.32
a Interaction with chemotherapy was between patients with EGFR gene amplification and wild-type patients.
b Sensitizing mutations included only exon 19 deletions and exon 21 L858R mutation; interaction with chemotherapy was between these EGFR-sensitizing mutant with wild-type
patients.
c High copy includes high polysomy and amplification, as defined by the University of Colorado EGFR scoring system.
EGFR, epidermal growth factor receptor.
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cluded in the models.23–26 Despite some imbalances in the
patient populations studied, the results of this study are
supportive of the hypothesis that the presence of an EGFR
TKD sensitizing mutation confers better overall survival for
all stages of NSCLC.
Aside from the prognostic importance of EGFR TK
domain mutations, this study also shows that patients with
exon 19 deletions or L858R EGFR sensitizing mutations
seem to derive greater benefit from chemotherapy than do
patients with wild-type tumors. This result is consistent with
several recent studies that have reported higher response rates
not only to EGFR TKIs but also to chemotherapy in both the
first-line and second-line advanced NSCLC settings when
EGFR mutations are present. In the Iressa pan-Asia Study
FIGURE 2. A, comparison of the survival of patients with EGFR  high polysomy and  high polysomy in the observation
arm. B, comparison of the survival of patients with EGFR amplification or no amplification in the observation arm. C, compari-
son of the survival of patients with EGFR  high polysomy in the chemotherapy and observation arms. D, comparison of the
survival of patients with EGFR high polysomy and amplification in the chemotherapy and observation arms. E, comparison of
the survival of patirents with wild-type EGFR, high polysomy and amplification in the chemotherapy and observation arms.
F, comparison of the survival of patients with EGFR amplification in the chemotherapy and observation arms. According to the
University of Colorado Cancer Center’s scoring criteria,21,22 low-EGFR gene copy number includes four categories (disomy, low
trisomy, high trisomy, and low polysomy) that are less than high polysomy, whereas high EGFR gene copy includes high poly-
somy and amplification (high polysomy). EGFR, epidermal growth factor receptor.
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trial that compared first-line gefitinib to paclitaxel/carboplatin
in Asian patients enriched for EGFR mutation, response in
patients with mutations was twofold higher in the chemother-
apy arm (47.3% versus 23.5%).13 There was also a trend
toward longer progression-free survival in the chemotherapy
arm for patients with mutations compared with patients with
wild-type tumors, although the difference was not statistically
significant (HR: 0.78, p  0.11). In the IRESSA NSCLC
Trial Evaluating Response and Survival against Taxotere
(INTEREST) trial that compared second-line gefitinib with
docetaxel in unselected patients, those with mutations also
demonstrated a twofold higher response rate to docetaxel than
patients with wild-type EGFR (21.1% versus 9.8%), and their
median survival on the docetaxel arm was also longer (16.6
months versus 6.0 months).16 In the two large phase III trials
that compared chemotherapy alone to chemotherapy and
cetuximab in advanced stage NSCLC, patients with EGFR
mutant tumors receiving chemotherapy alone also demon-
strated significantly longer survival with no differentially
greater benefit seen in patients treated with cetuximab.27,28
These four trials suggest that the presence of an EGFR
mutation is predictive of a differential response to chemo-
therapy. Nevertheless, because of the absence of untreated
control arms in these studies, it was not possible to determine
whether the presence of a mutation was predictive of a
differential survival benefit from chemotherapy.
There are fewer reports of the predictive effect of
EGFR mutation status in the adjuvant chemotherapy setting.
Suehisa et al.22 assessed mutation status in 187 Japanese
patients with adenocarcinoma (80% stage I) who had un-
dergone surgical resection at their institution. As in our own
study, survival of the 79 patients with mutations was superior,
but the difference was not significant (HR: 0.81, p  0.48).
Twenty-five patients with mutations received adjuvant uracil-
tegafur. When their survival was compared with that of the
remaining 54 patients with mutations who received no adju-
vant therapy, no significant survival benefit could be detected
(HR: 0.52, p  0.28). It is important to note, however, that
assignment to receive adjuvant therapy in this report was not
random but rather at the discretion of the treating physicians.
Furthermore, baseline patient and tumor characteristics were
not provided for patients who did and did not receive adju-
vant therapy. The effect of EGFR protein expression, al-
though not EGFR mutation status or copy number, in the
International Adjuvant Lung Trial (IALT) has been presented
in abstract form.29 No differential survival benefit from ad-
juvant platinum-based chemotherapy could be identified for
any degree of EGFR staining.
Thus, JBR.10 provides the first evidence to suggest
that, as in the advanced disease setting, patients with EGFR
mutations seem to derive greater survival benefit from post-
operative adjuvant platinum-based chemotherapy than do
patients with wild-type EGFR. Because only a small propor-
tion of tumors in JBR.10 had EGFR mutations, our study
lacked statistical power. Thus, our observations require con-
firmation. Nevertheless, such confirmation will have to come
from retrospective analyses of tumor bank specimens from
completed trials, as it is unlikely that further adjuvant che-
motherapy studies will ever be conducted with a no-treatment
arm. Furthermore, to have adequate power to detect statisti-
cally significant differences, meta-analyses may be required.
Despite using two additional sensitive methods (frag-
ment analysis and Amplified Refractory Mutation System),
the EGFR mutation rate detected in this cohort was at the
lower level of previously reported prevalence rates for EGFR
mutations in North American patients with NSCLC. We did
not search for other mutations including T790 M in this
analysis because they are not known to be associated with a
differential response to chemotherapy, and their extremely
low frequency would preclude meaningful observations or
conclusions in this study. Unexpectedly, the prevalence rate
of high EGFR gene copy number was greater than that
reported previously in many studies including BR.21 and
Iressa Survival Evaluation in Lung Cancer15,16 but consistent
with more recent results of FISH analysis in early-stage
resected NSCLC, which have reported prevalence rates rang-
ing from 50 to 74%.30,31
Several previous studies have reported that high EGFR
gene copy number (high polysomy and amplification) is
associated with poorer prognosis in patients with advanced
NSCLC,14,15 but comparable studies for unselected early-
stage surgically treated patients with NSCLC are limited.
Hirsch et al.32 reported that in 173 stage I to stage III resected
patients, high EGFR gene copy (balanced polysomy/amplifi-
cation) was associated with a trend toward shorter survival
(HR not reported, p  0.13). Liu et al. did not find any
significant effect of high polysomy (5 copies) as deter-
mined by chromogenic in situ hybridization in their study of
164 surgical patients from Taiwan (median survival 56.2
months versus 53.4 months). In our study, patients with high
gene copy number showed a trend toward better survival
compared with low copy number patients, but this seems to
be driven mainly by the high polysomy patients, as patients
with amplification demonstrated a trend toward poorer sur-
vival similar to that reported by Hirsch et al.32 These data
may suggest the presence of other good prognostic genes on
chromosome 7.
There is little evidence to suggest that EGFR copy
number is an important predictor of response to chemother-
apy, and results from the literature are variable. In the
advanced NSCLC first-line setting, Hirsch et al.18 reported
response rates to paclitaxel/carboplatin of 29.8% for high
copy patients versus 25.4% for low-copy patients in the
TRIBUTE trial. In Iressa pan-Asia Study,33 response rates to
the same chemotherapy regimen were higher in high than low
copy patients (44.8% versus 26.3%), but this may have been
driven by the large subpopulation of patients with mutations
within the high copy subgroup. In the INTEREST,14 where
the mutation rate was lower, response to docetaxel was
similar for high- and low copy patients (10.1% versus 7.4%),
as were median survivals (7.5 versus 7.7 months). In INVITE
(Iressa versus vinorelbine in chemonaive elderly patients with
advanced non-small cell lung cancer), a trial that compared
first-line gefitinib to single-agent vinorelbine in elderly pa-
tients,34 response according to EGFR copy number was not
reported. Nevertheless, high copy patients had a nonsignifi-
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cant trend toward improved overall survival compared with
low-copy patients (HR: 0.52, 95% CI: 0.25–1.10) in the
vinorelbine arm, and unexpectedly, high copy patients
seemed to derive greater survival benefit from vinorelbine
compared with gefitinib (HR: 1.61, 95% CI: 0.87–3.01, p: not
significant).
In this study, although the differences were not statis-
tically significant, there was a trend to suggest that high copy
patients possibly might derive greater benefit from the adju-
vant vinorelbine/cisplatin doublet studied in JBR.10. This
result would be in keeping with the superior survival seen
with single-agent vinorelbine in the INVITE study.34
In summary, the presence of EGFR-activating muta-
tions or high gene copy may affect survival benefit from
adjuvant chemotherapy. Confirmatory studies might be per-
formed more easily using tumor samples from placebo-
controlled adjuvant chemotherapy trials in East Asia where
the EGFR mutation rate is significantly higher. In studies
from Western countries, it may be necessary to pool results in
meta-analyses to have an adequate number of subjects with
mutations to achieve statistical significance. Meta-analyses
may also have the power to isolate the effect of high copy
number in patients with EGFR wild-type tumors. Our results
may provide some explanation as to why EGFR mutation and
gene copy are not as predictive in trials comparing EGFR
TKIs with chemotherapy, as the benefit of both therapies
seems to be higher in patients with EGFR mutant or high
copy tumors. Finally, the clinically meaningful survival ben-
efit from chemotherapy experienced by patients with EGFR
mutant tumors in BR.10 suggests that adjuvant chemotherapy
should not be withheld form these patients in favor of
treatment with an EGFR TKI. This is of particular importance
in view of the lack of survival benefit seen with adjuvant
gefitinib in the NCIC Clinical Trials Group BR.19 trial.35
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